Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003
نویسندگان
چکیده
منابع مشابه
Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
177Lu-DOTA-HH1 (177Lu-HH1) is a novel anti-CD37 radioimmunoconjugate developed to treat non-Hodgkin lymphoma. Mice with subcutaneous Ramos xenografts were treated with different activities of 177Lu-HH1, 177Lu-DOTA-rituximab (177Lu-rituximab) and non-specific 177Lu-DOTA-IgG1 (177Lu-IgG1) and therapeutic effect and toxicity of the treatment were monitored. Significant tumor growth delay and incre...
متن کاملNon-cytotoxic antibodies in chronic lymphocytic leukaemia.
Non-cytotoxic Fc receptor blocking antibodies against autologous B lymphocytes were sought in sera from patients with chronic lymphocytic leukaemia (CLL), using a rosette inhibition assay. They were found in 11 of 52 (21%) of patients with CLL, but were not associated with previous blood transfusion or pregnancy, suggesting that they were unlikely to have resulted from allogeneic stimulation. F...
متن کاملTargeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.
Alpha-emitting radionuclides are highly cytotoxic and are of considerable interest in the treatment of cancer. A particularly interesting approach is in radioimmunotherapy. However, alpha-emitting antibody conjugates have been difficult to exploit clinically due to the short half-life of the radionuclides, low production capability, or limited source materials. We have developed a novel technol...
متن کاملChronic lymphocytic leukaemia.
Chronic lymphocytic leukaemia is the commonest of the leukaemias and occurs most often in the elderly. The identification of presenting features that correlate adversely or favourably with survival has allowed the rational development of new treatment strategies.
متن کاملChronic lymphocytic leukaemia (CLL)
Typically, proliferation of mature small lymphocytes of normal morphology; lymphocytes with more abundant cytoplasm may be present. When prolymphocytes are 10% or greater they are classified as 'chronic lymphocytic leukaemia-prolymphocytic leukaemia'. The main immunophenotypic features that define BCLL are: the predominant population shares B-cell markers CD19, CD20, and CD23 with the CD5 antig...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: PLOS ONE
سال: 2020
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0230526